October 18th, 2013
OTD and HBS Welcome First Blavatnik Fellows
On October 17, OTD and HBS kicked-off the new fellowship program with a reception to welcome the inaugural fellows.
News
Press Contact: Kirsten Mabry | (617) 495-4157
Featured Tags:
July 15th, 2013
Ipsen announce a sponsored research agreement with Harvard Medical School to discover novel engineered botulinum toxins for serious neurologic diseases
Paris (France), 15 July 2013 - Ipsen (Euronext: IPN, ADR: IPSEY) announced today that it
has initiated a research and development collaboration on novel engineered botulinum toxins
with Harvard Medical School (Harvard).
Under the terms of the agreement, Ipsen will fund Harvard research for at least three years
with the aim to discover, evaluate and develop novel engineered recombinant botulinum
toxins for the treatment of serious neurologic diseases.
May 16th, 2013
Evotec and Harvard University to collaborate on development of new class of antibacterials
Target PGB (PEPTIDOGLYCAN BIOSYNTHESIS) is the focus of collaboration designed to develop novel family of antibacterial drugs based on highly validated target
April 29th, 2013
$50M gift from the Blavatnik Family Foundation
Harvard Gazette: Blavatnik Biomedical Accelerator a catalyst to transform early-stage research.
